
    
      This open-label, randomized phase II trial evaluates in parallel two doses of nab-Paclitaxel
      (100 and 125mg/m2) given weekly for 3 weeks every 28 days, in elderly women aged 65 years or
      older, as first line treatment for advanced breast cancer (locally recurrent or metastatic).
      A short geriatric evaluation of co-morbidity and functional status will be performed before
      study entry. The functional status will be monitored at baseline and at every cycles during
      treatment.
    
  